If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Sales and Marketing » Marketing Management » Designing Marketing Strategies » Product Positioning and Differentiation
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
This 4-page case study examines Zyprexa, the third atypical antipsychotic therapy when it was approved in 1996 by the FDA. Developed by Eli Lilly, Zyprexa went off patent in 2011 after a 15-year run that saw the drug generate more than $53 billion in sales. This study reviews Zyprexa's market position, side effect profile, as well as the clinical strategy & marketing tactics Lilly used to help make the product a blockbuster even in a crowded market.
This study reviews Zyprexa's strengths, weaknesses and marketing pitfalls that Lilly faced during the product's 1996-2011 period on the antipsychotic market.
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.